Literature DB >> 9626253

X-linked vacuolated myopathy: membrane attack complex deposition on the surface membrane of injured muscle fibers is not accompanied by S-protein.

J P Louboutin1, J M Navenot, M Villanova, K Rouger, L Merlini, M Fardeau.   

Abstract

We have studied the expression of S-protein on the muscle from patients with X-linked vacuolated myopathy [characterized by the deposition of the complement C5b-9 membrane attack complex (MAC) over abnormal muscle fibers] and controls by immunocytochemistry and immunoblotting. No expression was detected on muscle from controls and patients with X-linked vacuolated myopathy. These findings suggest that S-protein does not render the MAC inactive in X-linked vacuolated myopathy. This situation may be due to the fact that the pathways of MAC activation and the expression of S-protein in X-linked vacuolated myopathy are different from the ones observed in ischemic and/or necrotic, or immune diseases. These results emphasize the role of the membrane complement regulatory proteins (i.e., CD59) in X-linked vacuolated myopathy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9626253     DOI: 10.1002/(sici)1097-4598(199807)21:7<932::aid-mus11>3.0.co;2-s

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  3 in total

1.  Effect of complement and its regulation on myasthenia gravis pathogenesis.

Authors:  Linda L Kusner; Henry J Kaminski; Jindrich Soltys
Journal:  Expert Rev Clin Immunol       Date:  2008-01       Impact factor: 4.473

2.  Sarcolemmal Complement Membrane Attack Complex Deposits During Acute Rejection of Myofibers in Nonhuman Primates.

Authors:  Daniel Skuk; Jacques P Tremblay
Journal:  J Neuropathol Exp Neurol       Date:  2019-01-01       Impact factor: 3.685

3.  Distinct tissue injury patterns in juvenile dermatomyositis auto-antibody subgroups.

Authors:  Mailan Nguyen; Vy Do; Paul C Yell; Chanhee Jo; Jie Liu; Dennis K Burns; Tracey Wright; Chunyu Cai
Journal:  Acta Neuropathol Commun       Date:  2020-08-05       Impact factor: 7.801

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.